The risk of non-melanoma skin cancer in New Zealand in Inflammatory Bowel Disease patients treated with thiopurines.

Related Articles The risk of non-melanoma skin cancer in New Zealand in Inflammatory Bowel Disease patients treated with thiopurines. J Gastroenterol Hepatol. 2017 Nov 04;: Authors: Bahi M, Walmsley RS, Gray AR, Young D, Hobbs CE, Aluzaite K, Schultz M Abstract BACKGROUND AND AIM: New Zealand (NZ) has one of the highest rates of non-melanoma skin cancers (NMSC) in the world. Thiopurine use in Inflammatory Bowel Disease (IBD) patients has been shown to increase NMSC risk. This study aimed to investigate the possible increase of NMSC risk in thiopurine-treated IBD…

Read More

Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease.

Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease. J Gastroenterol Hepatol. 2017 Oct 31;: Authors: Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T, ADJUST study group Abstract BACKGROUND AND AIM: There are few studies on the long-term efficacy of adalimumab treatment for patients with Crohn’s disease. We have conducted a large, multicenter, retrospective cohort study…

Read More

Association of CDKN2A/B with inflammatory bowel disease in Koreans.

Related Articles Association of CDKN2A/B with inflammatory bowel disease in Koreans. J Gastroenterol Hepatol. 2017 Oct 24;: Authors: Lee HS, Lee SB, Kim BM, Hong M, Jung S, Hong J, Baek J, Han B, Oh SH, Kim KM, Park SH, Yang SK, Ye BD, Song K Abstract BACKGROUND AND AIM: CDKN2A/B locus on 9p21 is reported to be associated with various diseases, including cancer, cardiovascular and inflammatory diseases. Significant down-regulation of CDKN2B-AS1 in inflamed colon tissue of IBD cases was reported in Europeans. This study aimed to confirm the suggestive…

Read More

Trends in healthcare costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population-based study.

Trends in healthcare costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population-based study. J Gastroenterol Hepatol. 2017 Oct 21;: Authors: Kim JW, Lee CK, Rhee SY, Oh CH, Shim JJ, Kim HJ Abstract BACKGROUND AND AIMS: Data regarding healthcare costs and utilization for IBD at the population level are limited in Asia. We aimed to investigate the nationwide prevalence, and healthcare cost and utilization of IBD in Korea. METHODS: We tracked the IBD-attributable healthcare costs and utilization from 2010 to 2014 using the…

Read More

Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Park 1: risk assessment.

Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Park 1: risk assessment. J Gastroenterol Hepatol. 2017 Oct 10;: Authors: Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK Abstract Because anti-tumor necrosis factor (anti-TNF)…

Read More

Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.

Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. J Gastroenterol Hepatol. 2017 Oct 10;: Authors: Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK Abstract Because anti-tumor necrosis factor (anti-TNF) therapy…

Read More

Effects of R- and S-enantiomers of chiral non-steroidal anti-inflammatory drugs in experimental colitis.

Related Articles Effects of R- and S-enantiomers of chiral non-steroidal anti-inflammatory drugs in experimental colitis. J Gastroenterol Hepatol. 1998 Nov;13(S3):S266-S269 Authors: Reuter BK, Mauleón D, Wallace JL Abstract Prostaglandins appear to play an important role in down-regulating intestinal inflammation and promoting repair of injury. In experimental colitis, inhibition of prostaglandin synthesis with nonsteroidal anti-inflammatory drugs (NSAID) leads to marked exacerbation of tissue injury. It has been suggested that the ability of chiral NSAID to inhibit prostaglandin synthesis is completely attributable to the s-enantiomer, while the r-enantiomer is a much weaker…

Read More

Prolonged azathioprine treatment reduces the need for surgery in early Crohn’s disease.

Prolonged azathioprine treatment reduces the need for surgery in early Crohn’s disease. J Gastroenterol Hepatol. 2017 Sep 22;: Authors: Qiu Y, Chen BL, Feng R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Peyrin-Biroulet L, Mao R, Chen MH Abstract BACKGROUND AND AIM: Whether an early use of azathioprine (AZA) can alter the natural history of Crohn’s disease (CD) remains debated. To evaluate the impact of AZA on disease progression in a cohort of patients with early CD. METHODS: This longitudinal cohort study examined patients with early CD defined as…

Read More

Increased enteric glial cells in proximal margin of resection is associated with postoperative recurrence of Crohn’s disease.

Increased enteric glial cells in proximal margin of resection is associated with postoperative recurrence of Crohn’s disease. J Gastroenterol Hepatol. 2017 Sep 05;: Authors: Li Y, Ge Y, Zhu W, Gong J, Cao L, Guo Z, Gu L, Li J Abstract BACKGROUND AND AIM: The enteric nervous system can amplify or modulate intestinal inflammation through secretion of neuropeptides, and enteric glial cells has been implicated in the pathophysiology of Crohn’s disease. The goal of the study was to search for an association between the density of neurons, neuropeptides, as well…

Read More

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn’s disease.

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn’s disease. J Gastroenterol Hepatol. 2017 Aug 30;: Authors: Sugita N, Watanabe K, Kamata N, Yukawa T, Otani K, Hosomi S, Nagami Y, Tanaka F, Taira K, Yamagami H, Tanigawa T, Shiba M, Watanabe T, Tominaga K, Kabata D, Shintani A, Arakawa T, Fujiwara Y Abstract BACKGROUND AND AIM: Secondary loss of response to adalimumab (ADA-LOR) commonly occurs in patients with Crohn’s disease (CD) treated with ADA. We evaluated the efficacy of…

Read More
<< Go Back